Intermittent androgen ablation as a treatment for prostate cancer.
Wolff
J M
JM
Department of Urology, University of Rostock, Germany. johannes.wolff@med.uni-rostock.de
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004967:Estrogens / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000601:surgery; D051379:Mice; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000601:surgery; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000187:drug effects; D009919:Orchiectomy; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013739:Testosterone; D016896:Treatment Outcome
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D013739:Testosterone